Gallium-68 DOTATATE

Phase 1Radiopharmaceutical

SStanford University

Gallium-68 DOTATATE is one of 12 small molecule programs targeting Cardiac Sarcoidosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiac SarcoidosisActive, not recruiting

Gastroenteropancreatic Neuroendocrine TumorActive, not recruiting

Cardiac SarcoidosisPreclinical

Active, not recruiting

Gastroenteropancreatic Neuroendocrine TumorPhase 1

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Cardiac Sarcoidosis

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Approved

1 2

Trexall

Jazz Pharmaceuticals

Phase 3

1 3

Olumiant

Eli Lilly

Phase 2

1 4

Arcalyst

KKiniksa Pharmaceuticals (UK), Ltd.

Phase 2

1 5

Prednisone or Prednisolone

Johnson & Johnson

Phase 3

1 6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Inpefa

LLexicon Pharmaceuticals

Preclinical

—8

Tc-99m Tilmanocept

NNavidea Biopharmaceuticals

Phase 2

1 9

Gallium-68 DOTATATE

SStanford University

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Gastroenteropancreatic Neuroendocrine Tumor

NCT04609592

Clinical

Trials by Indication[1]

Cardiac Sarcoidosis2 trials

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

Completed·UUniversity of Pennsylvania··NCT03746847·20 enrolled

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

Completed·MMarcelo F. Di Carli, MD, FACC·N/A·NCT02546388·17 enrolled

Breast Cancer1 trial

Study of Dotatate Imaging in Breast Cancer

Unknown status·HHoag Memorial Hospital Presbyterian·Phase 2·NCT05880394·30 enrolled

Gastroenteropancreatic Neuroendocrine Tumor1 trial

Phase 1 Study of Perioperative Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumors Who Are Candidates for Cytoreductive Surgery

Active, not recruiting·SStanford University·Phase 1·NCT04609592·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Gallium-68 DOTATATE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium-68 DOTATATE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium-68 DOTATATE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: SStanford University

Gallium-68 DOTATATE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cardiac Sarcoidosis2 trials

Breast Cancer1 trial

Gastroenteropancreatic Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News